

FORM 51-102F3

MATERIAL CHANGE REPORT

1. Name and Address of Company

Opsens Inc. (« Opsens » or the « Corporation »)
2014 Cyrille-Duquet Street, Suite 125
Québec, Québec
G1N 4N6

2. Date of Material Change

November 19, 2014

3. News Release

A news release, in French and English versions, was issued through CNW Telbec on November 19, 2014, copies of which are attached hereto.

4. Summary of Material Change

Opsens granted CE marking for sale of FFR products in Europe.

5. Full Description of Material Change

5.1 Full Description of Material Change

Opsens announces it has been granted CE marking for OptoWire and OptoMonitor, which allows these products to be sold in Europe, the world's second largest market.

Following the recent Shonin approval in Japan, getting regulatory approval to market the products in Europe represents another very important step for the Corporation. The Corporation is now focusing its efforts on commercialization, with the imminent launch of its products in these territories

5.2 Disclosure for Restructuring Transactions

Not applicable.

6. Reliance on Subsection 7.1(2) of Regulation 51-102

Not applicable.

7. Omitted Information

Not applicable.

8. Executive Officer

For additional information, please contact:

Mr. Thierry Dumas

Chief Financial Officer

Phone: (418) 682-9996

9. Date of Report

November 27, 2015

Opsens Inc.

by: (s) *Thierry Dumas*
Thierry Dumas, Chief Financial Officer



PRESS RELEASE
For Immediate Dissemination

OPSENS GRANTED CE MARKING FOR SALE OF FFR PRODUCTS IN EUROPE

Quebec City, Quebec, November 19, 2014 - Opsens Inc. (TSXV:OPS) ("Opsens" or the "Company") is pleased to announce that it has been granted CE marking for OptoWire and OptoMonitor, which allows these Fractional Flow Reserve (FFR) products for patients with coronary artery disease to be marketed in Europe, the world's second largest market.

"Following the recent Shonin approval in Japan, getting regulatory approval to market our products in Europe represents another very important step for us. We are now focusing our efforts on commercialization, with the imminent launch of our products in these territories. We are looking optimistically forward to the next regulatory steps, which include receiving 510(k) approval from the US Food and Drug Administration (FDA), and Medical Device Licence from Health Canada" explained Louis Laflamme, president and CEO of Opsens.

Penetrating part of the FFR market will have a major impact on the Company's sales. In 2013, the FFR market had already exceeded US\$250 million, and market stakeholders expect it to reach US\$1 billion in the medium term.

The OptoWire is an optical pressure guidewire that measures intra-coronary blood pressure using unique patented technologies. Its sensing technology imperviousness to the undesirable effects of contact with blood and other fluids, coupled to effective and reliable connectivity provides reliable FFR readings in extended conditions of usage. The OptoWire is also designed to give cardiologists a guidewire that offers optimized performance for navigating inside coronary arteries and reaching blockages easily.

About Opsens Inc. (www.opsens.com)

Focusing on two main growth markets, FFR in medical instrumentation and oil and gas, Opsens develops, manufactures and installs systems to measure pressure, temperature and others parameters using fiber optic sensing technologies. These systems are designed around patented technologies that are effective and durable in extreme conditions.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements contained in this press release involve known and unknown risks, uncertainties and other factors that may cause actual results, performance and achievements of Opsens to be materially different from any future results, performance or achievements expressed or implied by the said forward-looking statements.

-30-

For further information, please contact:

Thierry Dumas, CPA, CA, Chief Financial Officer, 418.682.9996

Louis Laflamme, CPA, CA, President and Chief Executive Officer, 418.682.9996